Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $220.00

Krystal Biotech, Inc. (NASDAQ:KRYS) has received an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $220.00.

A number of brokerages recently issued reports on KRYS. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. Crossmark Global Holdings Inc. grew its position in shares of Krystal Biotech by 25.8% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 2,186 shares of the company’s stock valued at $398,000 after buying an additional 449 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its position in shares of Krystal Biotech by 93.1% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 2,591 shares of the company’s stock valued at $472,000 after purchasing an additional 1,249 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at about $235,000. KBC Group NV boosted its position in shares of Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after purchasing an additional 132 shares in the last quarter. Finally, Huntington National Bank boosted its position in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after purchasing an additional 283 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Up 0.4 %

Shares of NASDAQ KRYS opened at $189.18 on Monday. The company has a market cap of $5.45 billion, a P/E ratio of 63.27 and a beta of 0.87. Krystal Biotech has a 12 month low of $141.72 and a 12 month high of $219.34. The business’s 50 day moving average is $165.34 and its two-hundred day moving average is $173.69.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business’s revenue was up 116.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.30 earnings per share. Sell-side analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).